Efficacy of Quinoxaline-2-Carboxylate 1,4-Di- N -Oxide Derivatives in Experimental Tuberculosis
- 1 September 2008
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (9) , 3321-3326
Abstract
This study extends earlier reports regarding the in vitro efficacies of the 1,4-di- N -oxide quinoxaline derivatives against Mycobacterium tuberculosis and has led to the discovery of a derivative with in vivo efficacy in the mouse model of tuberculosis. Quinoxaline-2-carboxylate 1,4-di- N -oxide derivatives were tested in vitro against a broad panel of single-drug-resistant M. tuberculosis strains. The susceptibilities of these strains to some compounds were comparable to those of strain H 37 Rv, as indicated by the ratios of MICs for resistant and nonresistant strains, supporting the premise that 1,4-di- N -oxide quinoxaline derivatives have a novel mode of action unrelated to those of the currently used antitubercular drugs. Specific derivatives were further evaluated in a series of in vivo assays, including evaluations of the maximum tolerated doses, the levels of oral bioavailability, and the efficacies in a low-dose aerosol model of tuberculosis in mice. One compound, ethyl 7-chloro-3-methylquinoxaline-2-carboxylate 1,4-dioxide, was found to be (i) active in reducing CFU counts in both the lungs and spleens of infected mice following oral administration, (ii) active against PA-824-resistant Mycobacterium bovis , indicating that the pathway of bioreduction/activation is different from that of PA-824 (a bioreduced nitroimidazole that is in clinical trials), and (iii) very active against nonreplicating bacteria adapted to low-oxygen conditions. These data indicate that 1,4-di- N -oxide quinoxalines hold promise for the treatment of tuberculosis.Keywords
This publication has 34 references indexed in Scilit:
- Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2007
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Extensively drug resistant tuberculosis: Problem will get worse in South Africa unless poverty is alleviatedBMJ, 2006
- Extensively drug resistant tuberculosis: Beware patients lost to follow-upBMJ, 2006
- Extensively drug resistant tuberculosisBMJ, 2006
- Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Demonstration that fbiC Is Required by Mycobacterium bovis BCG for Coenzyme F 420 and FO BiosynthesisJournal of Bacteriology, 2002
- Use of Transposon Tn 5367 Mutagenesis and a Nitroimidazopyran-Based Selection System To Demonstrate a Requirement for fbiA and fbiB in Coenzyme F 420 Biosynthesis by Mycobacterium bovis BCGJournal of Bacteriology, 2001
- ChemInform Abstract: Antimycobacterial Activity of New Quinoxaline-2-carbonitrile and Quinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives.ChemInform, 2001
- ChemInform Abstract: Synthesis and Antituberculosis Activity of New 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides.ChemInform, 1999